Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CTH | P32929 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | PLAU | P00749 | 1/20 | 0.30 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.30 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18674209 | 0.84 | GBA1 (0.33) | GBA1KDM4EALDH1A1 | |
| SCHEMBL1818004 | 0.79 | GBA1 (0.36) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL31169366 | 0.79 | GBA1 (0.36) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL15001190 | 0.78 | GBA1 (0.35) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL15001209 | 0.78 | GBA1 (0.35) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL15001188 | 0.78 | GBA1 (0.35) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL1818566 | 0.75 | GBA1 (0.41) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL29926723 | 0.74 | GBA1 (0.41) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL681100 | 0.74 | GBA1 (0.41) | GBA1KDM4EALDH1A1PDE10APLAU | |
| SCHEMBL508438 | 0.74 | GBA1 (0.33) | GBA1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974786-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2018-05-22 | — | — | US | disclosed |
| US-9795603-B2 | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use | SIGNAL PHARMACEUTICALS, LLC (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170182042-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | SIGNAL PHARM LLC (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182042-A1 | PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE | CYP11B2, CYP27A1, CYP11B1 | GBA1 306/4885KDM4E 3600/4885ALDH1A1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.